Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group

E B Keeffe1, F B Hollinger

  • 1Department of Medicine, Stanford University School of Medicine, CA, USA.

Hepatology (Baltimore, Md.)
|September 26, 1997
PubMed
Summary

Consensus interferon (CIFN) at 9 mcg demonstrated safety and efficacy for chronic hepatitis C, showing sustained response rates comparable to interferon alfa-2b. Higher CIFN doses (15 mcg) proved effective for retreatment in relapsed or non-responsive patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Employment after liver transplantation: a review.

Transplantation proceedings·2015
Same author

Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review.

Journal of viral hepatitis·2014
Same author

Psychological assessment of quality of life following liver transplantation.

Journal of clinical psychology in medical settings·2013
Same author

Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients.

Journal of viral hepatitis·2012
Same author

Risk assessment for hepatocellular carcinoma in chronic hepatitis B: scores and surveillance.

International journal of clinical practice·2011
Same author

Review article: current antiviral therapy of chronic hepatitis B.

Alimentary pharmacology & therapeutics·2011

Area of Science:

  • Hepatology and Viral Gastroenterology
  • Immunology and Infectious Diseases

Background:

  • Chronic hepatitis C (HCV) is a significant global health concern, leading to substantial morbidity and mortality.
  • Alpha interferons are the sole approved therapies for chronic HCV, necessitating the exploration of novel treatment options.

Purpose of the Study:

  • To evaluate the efficacy and safety of Consensus Interferon (CIFN) as a treatment for chronic hepatitis C.
  • To compare CIFN's effectiveness against standard interferon alfa-2b therapy in initial treatment and retreatment settings.

Main Methods:

  • Two Phase 3 multicenter, randomized, double-blind, controlled trials were conducted.
  • Trial 1: 704 patients treated with CIFN (3 or 9 mcg) or interferon alfa-2b (3 MU) weekly for 24 weeks.
  • Trial 2: Patients relapsed or non-responsive to prior therapy were retreated with CIFN (15 mcg) for 24 or 48 weeks.

Related Experiment Videos

Main Results:

  • CIFN 9 mcg showed comparable sustained response rates (20% ALT, 12% HCV RNA) to interferon alfa-2b.
  • Undetectable serum HCV RNA at 2 weeks (48%) and 12 weeks (96%) predicted sustained response.
  • CIFN 15 mcg retreatment yielded higher sustained response rates in relapsers (28-58%) versus non-responders (5-13%).

Conclusions:

  • Consensus Interferon (CIFN) at 9 mcg is an effective initial therapy for chronic hepatitis C.
  • Retreatment with CIFN 15 mcg for 48 weeks offers meaningful responses in both relapsed and non-responder patients.
  • CIFN was well-tolerated, with adverse effects similar to interferon alfa-2b.